Tandem Diabetes Care (TNDM) Revenue Growth (3y) (2016 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn | 4.63% |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn | 8.01% |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn | 5.28% |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn | 15.36% |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn | 10.52% |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | 0.73% |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn | 17.14% |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn | 2.92% |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn | 7.43% |
| 10 | Tandem Diabetes Care | 1.31 Bn | 739.55 Mn | 136.79 Mn | 13.43% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 13.43% |
| Dec 31, 2025 | 9.61% |
| Sep 30, 2025 | 6.81% |
| Jun 30, 2025 | 6.32% |
| Mar 31, 2025 | 10.05% |
| Dec 31, 2024 | 10.41% |
| Sep 30, 2024 | 10.74% |
| Jun 30, 2024 | 8.83% |
| Mar 31, 2024 | 10.77% |
| Dec 31, 2023 | 5.40% |
| Sep 30, 2023 | 14.52% |
| Jun 30, 2023 | 21.50% |
| Mar 31, 2023 | 20.04% |
| Dec 31, 2022 | 26.71% |
| Sep 30, 2022 | 29.28% |
| Jun 30, 2022 | 29.02% |
| Mar 31, 2022 | 38.65% |
| Dec 31, 2021 | 40.20% |
| Sep 30, 2021 | 57.17% |
| Jun 30, 2021 | 71.50% |
| Mar 31, 2021 | 72.92% |
| Dec 31, 2020 | 60.97% |
| Sep 30, 2020 | 66.04% |
| Jun 30, 2020 | 72.38% |
| Mar 31, 2020 | 72.81% |
| Dec 31, 2019 | 55.35% |
| Sep 30, 2019 | 97.47% |
| Jun 30, 2019 | 59.49% |
| Mar 31, 2019 | 48.73% |
| Dec 31, 2018 | 37.80% |
| Sep 30, 2018 | 43.32% |
| Jun 30, 2018 | 29.52% |
| Mar 31, 2018 | 30.38% |
| Dec 31, 2017 | 31.08% |
| Sep 30, 2017 | 25.96% |
| Jun 30, 2017 | 27.65% |
| Mar 31, 2017 | 33.00% |
| Dec 31, 2016 | 41.32% |
| Sep 30, 2016 | 16.49% |
| Jun 30, 2016 | 60.80% |
| Mar 31, 2016 | 54.32% |